Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naive Hepatitis C-infected, Genotype 1 Patients.

Trial Profile

A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naive Hepatitis C-infected, Genotype 1 Patients.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tilsotolimod (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Aceragen; Idera Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 11 Mar 2011 Status changed from recruiting to completed based on information reported in an Idera Pharmaceuticals media release.
    • 21 Dec 2010 Preliminary results have been announced in an Idera Pharmaceuticals media release, and are expected to be presented at a scientific meeting in 2011.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top